Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age
ObjectiveTo evaluate the safety and efficacy of the Medtronic 780G SmartGuard™ AID system in children under 7 years of age with type 1 diabetes (T1D).MethodsRetrospective analysis of data from children living with T1D under 7 years of age using the MiniMed 780G™ across three pediatric endocrinology...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1465800/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558762408640512 |
|---|---|
| author | Sara López-López Cristina Díaz-Martín Inés García-de Pablo María Teresa Ovejero-Garcia María Beatriz Garnier-Rodríguez Ruth Molina-Suárez Cristina Ontoria-Betancort Blanca Sáez-Gallego Ángela Domínguez-García Sofía Quinteiro-González Lourdes Travieso-Suárez María Fátima Cabrera-Guedes Yeray Nóvoa-Medina Yeray Nóvoa-Medina Yeray Nóvoa-Medina |
| author_facet | Sara López-López Cristina Díaz-Martín Inés García-de Pablo María Teresa Ovejero-Garcia María Beatriz Garnier-Rodríguez Ruth Molina-Suárez Cristina Ontoria-Betancort Blanca Sáez-Gallego Ángela Domínguez-García Sofía Quinteiro-González Lourdes Travieso-Suárez María Fátima Cabrera-Guedes Yeray Nóvoa-Medina Yeray Nóvoa-Medina Yeray Nóvoa-Medina |
| author_sort | Sara López-López |
| collection | DOAJ |
| description | ObjectiveTo evaluate the safety and efficacy of the Medtronic 780G SmartGuard™ AID system in children under 7 years of age with type 1 diabetes (T1D).MethodsRetrospective analysis of data from children living with T1D under 7 years of age using the MiniMed 780G™ across three pediatric endocrinology units in the Canary Islands. Metabolic control parameters were analyzed from 14 days of pretreatment to 12 months of follow-up.ResultsThe study included 61 children under 7 years of age, 35 in Group 1 and 26 in Group 2. In Group 1, there was a significant increase in time in range (TIR) (13%, p = 0,000), along with a significant decrease in time above range (TAR) (7% for TAR1 and 3% for TAR2; p = 0,000). These improvements persisted for up to 1 year of follow-up. In Group 2, there was a significant increase in the TIR (7%; p = 0,000) and a significant decrease in the TAR (7%; p = 0,000 for TAR1 and 6.5%; p = 0,001 for TAR2). These improvements persisted for up to 6.5 months of follow-up. No significant changes were observed in the time below range (TBR) or variation coefficient (CV) in either group. No events of severe hypoglycemia or diabetic ketoacidosis occurred. Efficacy and safety were maintained in children with a TDD <8 units/day.ConclusionThe use of the Medtronic 780G™ SmartGuard™ system in children under 7 years of age with T1D is effective and safe, with benefits persisting for up to 6–12 months. The safety profile is maintained in children receiving a TDD <8 units/day. |
| format | Article |
| id | doaj-art-435963b2911e4d1392ac8f45915a2d73 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-435963b2911e4d1392ac8f45915a2d732025-01-06T05:13:17ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.14658001465800Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of ageSara López-López0Cristina Díaz-Martín1Inés García-de Pablo2María Teresa Ovejero-Garcia3María Beatriz Garnier-Rodríguez4Ruth Molina-Suárez5Cristina Ontoria-Betancort6Blanca Sáez-Gallego7Ángela Domínguez-García8Sofía Quinteiro-González9Lourdes Travieso-Suárez10María Fátima Cabrera-Guedes11Yeray Nóvoa-Medina12Yeray Nóvoa-Medina13Yeray Nóvoa-Medina14Complejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas de Gran Canaria, Gran Canaria, SpainHospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, SpainHospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, SpainHospital Universitario de Canarias, La Laguna, Tenerife, SpainHospital Universitario de Canarias, La Laguna, Tenerife, SpainHospital Universitario de Canarias, La Laguna, Tenerife, SpainHospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, SpainHospital Universitario de Canarias, La Laguna, Tenerife, SpainComplejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas de Gran Canaria, Gran Canaria, SpainComplejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas de Gran Canaria, Gran Canaria, SpainComplejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas de Gran Canaria, Gran Canaria, SpainComplejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas de Gran Canaria, Gran Canaria, SpainComplejo Hospitalario Universitario Insular Materno Infantil de Canarias, Las Palmas de Gran Canaria, Gran Canaria, SpainInstituto Universitario de Investigaciones Biomédicas y Sanitarias, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, SpainAsociación Canaria para la Investigación Pediátrica (ACIP Canarias), Las Palmas de Gran Canaria, SpainObjectiveTo evaluate the safety and efficacy of the Medtronic 780G SmartGuard™ AID system in children under 7 years of age with type 1 diabetes (T1D).MethodsRetrospective analysis of data from children living with T1D under 7 years of age using the MiniMed 780G™ across three pediatric endocrinology units in the Canary Islands. Metabolic control parameters were analyzed from 14 days of pretreatment to 12 months of follow-up.ResultsThe study included 61 children under 7 years of age, 35 in Group 1 and 26 in Group 2. In Group 1, there was a significant increase in time in range (TIR) (13%, p = 0,000), along with a significant decrease in time above range (TAR) (7% for TAR1 and 3% for TAR2; p = 0,000). These improvements persisted for up to 1 year of follow-up. In Group 2, there was a significant increase in the TIR (7%; p = 0,000) and a significant decrease in the TAR (7%; p = 0,000 for TAR1 and 6.5%; p = 0,001 for TAR2). These improvements persisted for up to 6.5 months of follow-up. No significant changes were observed in the time below range (TBR) or variation coefficient (CV) in either group. No events of severe hypoglycemia or diabetic ketoacidosis occurred. Efficacy and safety were maintained in children with a TDD <8 units/day.ConclusionThe use of the Medtronic 780G™ SmartGuard™ system in children under 7 years of age with T1D is effective and safe, with benefits persisting for up to 6–12 months. The safety profile is maintained in children receiving a TDD <8 units/day.https://www.frontiersin.org/articles/10.3389/fmed.2024.1465800/fulltype 1 diabetesclosed-loopchildrenautomated insulin deliverytreatment |
| spellingShingle | Sara López-López Cristina Díaz-Martín Inés García-de Pablo María Teresa Ovejero-Garcia María Beatriz Garnier-Rodríguez Ruth Molina-Suárez Cristina Ontoria-Betancort Blanca Sáez-Gallego Ángela Domínguez-García Sofía Quinteiro-González Lourdes Travieso-Suárez María Fátima Cabrera-Guedes Yeray Nóvoa-Medina Yeray Nóvoa-Medina Yeray Nóvoa-Medina Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age Frontiers in Medicine type 1 diabetes closed-loop children automated insulin delivery treatment |
| title | Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age |
| title_full | Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age |
| title_fullStr | Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age |
| title_full_unstemmed | Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age |
| title_short | Real world efficacy and safety of the advanced hybrid closed-loop system MiniMed 780G (SmartGuard) in children under 7 years of age |
| title_sort | real world efficacy and safety of the advanced hybrid closed loop system minimed 780g smartguard in children under 7 years of age |
| topic | type 1 diabetes closed-loop children automated insulin delivery treatment |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1465800/full |
| work_keys_str_mv | AT saralopezlopez realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT cristinadiazmartin realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT inesgarciadepablo realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT mariateresaovejerogarcia realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT mariabeatrizgarnierrodriguez realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT ruthmolinasuarez realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT cristinaontoriabetancort realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT blancasaezgallego realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT angeladominguezgarcia realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT sofiaquinteirogonzalez realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT lourdestraviesosuarez realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT mariafatimacabreraguedes realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT yeraynovoamedina realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT yeraynovoamedina realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage AT yeraynovoamedina realworldefficacyandsafetyoftheadvancedhybridclosedloopsystemminimed780gsmartguardinchildrenunder7yearsofage |